

A1 alkanoyl group, an aroyl group, a C₁₋₆ alkane sulphonyl or halogenated methane sulphonyl group, or an arene sulphonyl group.

8(Amended). Compounds of formula (I) as claimed in claim 1 wherein R⁵ represents a hydrogen atom or a methoxy group.

A2 9(Amended). Compounds of formula (I) as claimed in claim 1 wherein X represents a hydroxyl group or a group of formula NR⁶R⁷ wherein:

R⁶ is a C₁₋₆ alkyl group, C₆₋₁₂ carbocyclic aryl C₁₋₄ alkyl group, C₁₋₆ alkanoyl group, C₆₋₁₂ carbocyclic aryl C₂₋₅ alkanoyl group, C₇₋₁₃ carbocyclic aroyl group or any of the preceding groups substituted by one or more halo, C₁₋₄ alkyl, C₁₋₄ alkoxy, C₁₋₄ alkanoyl, C₁₋₄ alkylamino, di (C₁₋₄ alkyl) amino, nitro, carbamoyl or C₁₋₄ alkanoylamino substituents; and

R⁷ is a hydrogen atom or a C1-6 alkyl group.

A3 11(Amended). Compounds of formula (I) as claimed in claim 1 wherein Y contains up to 7 carbon atoms and up to 3 multiple bonds.

A4 13(Amended). Compounds of formula (I) as claimed in claim 1 wherein Y is substituted by a hydroxyl, etherified hydroxyl or esterified hydroxyl group positioned α-, β- or γ- to the group -C(R¹) (R²), X or α- to any triple bond present in the group Y.

AS 17(Amended). Active compound of formula (I) as claimed in claim 1 for use in management of neoplastic disease; as agents to promote wound healing; in burn management; in treatment of bone diseases, autoimmune disease, host-graft reaction, transplant rejection, inflammatory diseases, neoplasias or hyperplasias, myopathy, enteropathy or spondylitic heart disease; in suppression of parathyroid hormone; in treatment of dermatological diseases, hypertension, rheumatoid arthritis, psoriatic arthritis, secondary hyperparathyroidism, asthma, cognitive impairment or senile

AS dementia; in fertility control in either human or animal subjects; in management of disorders involving blood clotting; or in reduction of serum cholesterol.

AB 19(Amended). Pharmaceutical compositions comprising an active compound of formula (I) as claimed in claim 1 in admixture with one or more physiologically acceptable carriers or excipients.

20(Amended). A method of treatment of a human or animal subject in the management of neoplastic disease; to promote wound healing; in burn management; in treatment of bone diseases, autoimmune disease, host-graft reaction, transplant rejection, inflammatory diseases, neoplasias or hyperplasias, myopathy, enteropathy or spondylitic heart disease; in suppression of parathyroid hormone; in treatment of dermatological diseases, hypertension, rheumatoid arthritis, psoriatic arthritis, secondary hyperparathyroidism, asthma, cognitive impairment or senile dementia; in fertility control; in management of disorders involving blood clotting; or in reduction of serum cholesterol, which method comprises administering to said subject a therapeutically effective amount of an active compound of formula (I) as claimed in claim 1.

Please cancel claim 18 without prejudice or disclaimer.